Physician profile
Alejandro Barba Plan
NPI 1477660041
$2,192.45
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $449 · 2021: $853 · 2022: $269.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $576.89 | 2019-2022 | |
| Lilly USA, LLC | $429.61 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $183.37 | 2019-2022 | |
| Novo Nordisk INC | $136.67 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $133.94 | 2019-2022 | |
| Insulet Corporation | $124.74 | 2021-2022 | |
| Medtronic Minimed, INC. | $109.77 | 2019-2020 | |
| Medtronic, INC. | $79.66 | 2021-2022 | |
| Dexcom, INC. | $68.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.12 | 2019-2021 | |
| Corcept Therapeutics | $57.49 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $51.05 | 2019-2020 | |
| Abbott Laboratories | $50.57 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $35.22 | 2021 | |
| Amgen INC. | $28.59 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $25.69 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.46 | 2022 | |
| Sun Pharmaceutical Industries INC. | $18.76 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Plan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.